Skip to main content

Table 2 Association between ERCC1 staining results and prostate cancer clinical characteristics

From: Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer

  ERCC1 (%)   
Parameter n evaluable Negative Weak Moderate Strong p value
All cancers 10,436 35.4 37.1 22.6 5.0  
Tumor stage
pT2 6790 38.4 37.3 20.1 4.2 <0.0001
pT3a 2299 31.6 35.5 26.4 6.6
pT3b-pT4 1308 26.4 38.8 28.5 6.3
Gleason grade
≤3 + 3 2363 46.3 34.2 16.5 3.0 <0.0001
3 + 4 5630 34.7 37.4 22.9 5.0
3 + 4 Tert.5 368 33.4 40.8 22.0 3.8
4 + 3 1040 25.6 38.8 28.4 7.3
4 + 3 Tert.5 563 23.4 40.0 29.1 7.5
≥4 + 4 466 25.8 38.2 29.0 7.1
Lymph node metastasis
N0 5856 32.7 37.6 23.9 5.8 0.0037
N+ 585 25.6 39.8 27.9 6.7
Preoperative PSA level (ng/ml)
<4 1293 32.6 40.5 21.9 4.9 0.0078
4–10 6256 35.2 37.8 22.1 4.8
10–20 2058 37.5 33.9 23.5 5.1
>20 714 35.6 33.9 24.8 5.7
Surgical margin
Negative 8294 36.1 37.5 21.8 4.7 <0.0001
Positive 1953 32.7 35.5 25.9 5.9